Regeneron teams up with Gary Nabel’s ModeX on multispecificsnews2025-10-29T14:22:25+00:00October 29th, 2025|Endpoints News|
Scribing startups are reinventing themselves beyond notetaking as shakeout nearsnews2025-10-29T13:00:07+00:00October 29th, 2025|Endpoints News|
Weight loss drugs could be cost-effective even at higher prices, ICER saysnews2025-10-29T12:21:07+00:00October 29th, 2025|Endpoints News|
GSK trims pipeline, bumps guidance in Emma Walmsley’s last earnings reportnews2025-10-29T11:34:00+00:00October 29th, 2025|Endpoints News|
BridgeBio gets another Phase 3 rare disease win, this time in thyroid disordernews2025-10-29T11:00:39+00:00October 29th, 2025|Endpoints News|
WuXi AppTec to shutter Texas-based clinical research business news2025-10-29T10:31:41+00:00October 29th, 2025|Endpoints News|
DNA-chopping enzyme that breaks up NETs may offer new way to fight autoimmune disease, early data from Neutrolis suggestnews2025-10-29T10:00:58+00:00October 29th, 2025|Endpoints News|
Lilly keeps up legal fight against GLP-1 compounders news2025-10-28T19:40:58+00:00October 28th, 2025|Endpoints News|
FDA clears at-home use for Delix’s next neuroplastogen studynews2025-10-28T19:22:46+00:00October 28th, 2025|Endpoints News|
Everlywell’s at-home testing business evolutionnews2025-10-28T18:53:09+00:00October 28th, 2025|Endpoints News|
